A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Stopped Due to company decision to focus resources on a larger, controlled study in this patient population.

Conditions

• Myelodysplastic Syndromes
• Anemia

Interventions

• DRUG: Epoetin alfa

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

• [object Object]